The promise of multi-cancer early detection testing is that patients would have a single non-invasive test that could detect most types of cancer, and at an earlier stage than typically occurs now. Validating that MCEDs result in significant stage-shifting can be achieved, but it is far from easy and many questions about implementation require further study and experience. Clinical results point to greater detection of more aggressive cancers, which helps address the concern about potential over-diagnosis. The reduced capability to detect cancer at Stage 2, much less at Stage 1, compared to detection of later stages, and lower sensitivity for certain types of cancer, is concerning, but steady improvement in this performance can be expected. Adding testing for additional classes of biomarkers might also improve early sensitivity but would add to the cost of already expensive tests. The ability to conduct smaller and shorter clinical trials based on stage-shifting would be very helpful, as relying on the gold standard of reductions in mortality is very slow and expensive. As detection of more cases at earlier stages occurs, it will become more important to be able to better differentiate between aggressive and more benign cases. Greater early cancer detection may also increase demand for therapeutics that are less toxic than many drugs aimed at treatment of Stage 3 or 4 cancers. Looking even further out, what is the potential for adding biomarkers for early detection of other health conditions, besides cancer, for an even broader early detection screen?